ライフサイエンスコーパス: consent

1 on to treat (excluding patients who withdrew consent).

2 ncluded in the analysis (3 patients withdrew consent).

3 randomisation and those who did not provide consent).

4 ses at the time of randomization; 2 withdrew consent).

5 bations were recruited after giving informed consent.

6 l issues in recruitment and written informed consent.

7 r/recipient matching and to improve informed consent.

8 ticipants were deemed ineligible or withdrew consent.

9 clinically stable enough to provide informed consent.

10 protocol, and all participants gave informed consent.

11 unacceptable toxic effects, or withdrawal of consent.

12 s practice and the need for informed patient consent.

13 erdoses and provide information for informed consent.

14 0th and 11th 2015 following written informed consent.

15 e also considering raising the age of sexual consent.

16 in the ICU, of which 1458 provided informed consent.

17 ncern regarding the validity of anticipatory consent.

18 for a personalized written patient informed consent.

19 sion, intolerable toxicity, or withdrawal of consent.

20 common reason for not proceeding followed by consent.

21 ublished literature about the use of bundled consent.

22 ART were enrolled in the trial after giving consent.

23 ical care procedures with the use of bundled consent.

24 for more than 1 year, and provided informed consent.

25 recruited subjects provided written informed consent.

26 acetamol overdose, and gave written informed consent.

27 A common theme was the lack of voluntary consent.

28 her poor clinical condition or withdrawal of consent.

29 d 11 October 2015 following written informed consent.

30 oxicity, loss to follow-up, or withdrawal of consent.

31 uestionnaire, and all patients gave informed consent.

32 nce, unacceptable toxicity, or withdrawal of consent.

33 ts who were referred for transplant provided consent.

34 after explaining the procedure and acquiring consent.

35 ion, unacceptable toxicity, or withdrawal of consent.

36 -parkinsonian medications for 28 days before consent.

37 ticipate in the study, 2424 of whom provided consent.

38 sion, intolerable toxicity, or withdrawal of consent.

39 ed from the patient after obtaining informed consent.

40 chotic, or unable to give informed assent or consent.

41 , and were willing and able to give informed consent.

42 t boys/girls from 1992 to 1995 birth cohorts consented.

43 was only enrolled if at least 70% of members consented.

44 ecome organ donors than those not personally consenting.

45 rses declined to participate after initially consenting.

46 ishing and maintaining legitimacy and public consent(1-5).

47 Overall, 303 patients consented; 107 (35%; 69 in arm A and 38 in arm B) were e

48 posed by portable neuroimaging: (1) informed consent; (2) privacy; (3) capacity to accurately communi

49 study qualified for exception from informed consent (21 Code of Federal Regulations 50.24).

50 moval of those who declined or had withdrawn consent, 2463 (95%) were included in the analysis of the

51 second-line treatment and those who did not consent, 286 randomised participants were treated and ha

52 of 1031 patients screened were eligible and consented: 360 were randomly assigned to white light col

53 ed invasive bacterial infection who provided consent (38 152 inpatients, 16 596 outpatients).

54 In contrast, all six patients who consented 6-12 months posttransplant received the cell i

55 Twenty-one LTRs consented; 6 were excluded due to subclinical acute reje

56 Twenty-one LTR were consented; 6 were excluded due to subclinical AR on base

57 avoided through an ethical waiver to patient consent; a mixture of rural, urban, district, and univer

58 21 (0.4%) patients immediately withdrew consent after randomisation and were excluded.

59 e who were considered ineligible or withdrew consent after randomisation) was used in primary and saf

60 cannulation, but excluded those who withdrew consent after randomisation.

61 83 patients withdrew consent after the ERCP procedure, thus 1920 patients wer

62 Informed written consent and assent will be obtained before enrollment.

63 ging such risk factors can guide appropriate consent and clinical decision-making that may reduce ana

64 randomly assigned patients who gave informed consent and excluded those without 6-month outcome measu

65 patients were enrolled after giving informed consent and fulfilling study entry criteria.

66 ired bundled consent process actually obtain consent and how they perceive the overall value, efficac

67 ethod for improving both rates of documented consent and patient/family satisfaction, but there has b

68 h/ICU) and reasons for trial exclusion, high consent and protocol adherence rates (> 92%), infrequent

69 The median time between consent and transplantation of a kidney from an HCV-vire

70 1%) patient in the ribaxamase group withdrew consent and was not treated with ribaxamase.

71 0 children aged 5 years or younger, provided consent and were enrolled between May 22 and July 20, 20

72 ures during FIRE AND ICEwere retrospectively consented and enrolled at 13 trial centers.

73 secutive patients 18 to 90 years of age were consented and underwent an 80-gene panel test.

74 Twenty-four participants consented and were randomly assigned to complete 12-week

75 ts of close contacts of EVD cases, 210 (32%) consented and were vaccinated with rVSVDeltaG-ZEBOV-GP.

76 21 volunteers were eligible and provided consent, and all 21 completed 48 weeks of follow-up.

77 ) couples did not consent to WES or withdrew consent, and five (1%) samples were not of good enough q

78 ments, allowing adolescents to independently consent, and implementing surrogate decision making.

79 dequacy of participant protections, informed consent, and participant understanding of the risks and

80 of health privacy; the importance of equity, consent, and patient governance in data collection; disc

81 ding parents' perceived utility, adequacy of consent, and potential harms and benefits is lacking.

82 ures substudy; 1,265 (95%) of 1,333 patients consented, and 557 (58%) of 962 reported no moderate/mar

83 atients (defined as those who were eligible, consented, and received any protocol treatment) initiati

84 Ideally, individuals should give consent at the time of NGS testing to receive informatio

85 l problems and people who lacked capacity to consent at the time of recruitment.

86 (n = 10) undergoing TURP were prospectively consented based on their having a low risk of harbouring

87 e (2%) patient from the HF-HD group withdrew consent before receiving treatment.

88 ust have taken place at least 2 weeks before consent but less than 36 months previously.

89 not recommend specific age limits for sexual consent but urge recognition of adolescents as rights ho

90 in their perception of the value of bundled consent, but most (78%) felt it scared or stressed famil

91 nt after January 26, 2018, were educated and consented by protocol on the transplantation of HCV-vire

92 Laws that increase the age of sexual consent can be harmful and are often used to curb adoles

93 However, ethical challenges regarding consent can hinder adolescent research participation.

94 Of the 125 consented cases, 101 (81%) developed brain death (BD), m

95 ruing data up to date, comply with potential consent changes, and efficiently and reproducibly extrac

96 A quota of 35 consenting childcare centers undertook child-level evalu

97 wing which 1295 families were approached for consent; consent was provided for MITS by 963 (74%) of 1

98 ed follow-up provided their written informed consent (data cutoff: December 31, 2016).

99 , began a new anticancer treatment, withdrew consent, died, had stable disease for 6 weeks or longer,

100 11% reported conducting a complete informed consent discussion for each procedure.

101 ced the centrality of the risk/benefit-based consent discussion.

102 60 patients withdrew consent during the course of the trial (35 in the interv

103 own cause during follow-up), 1 withdrawal of consent during treatment, 2 relapses during follow-up, a

104 to thousands of participants (with explicit consent), enabling advances in vision research, accessib

105 ible for identifying participants, obtaining consent, enrolment, and outcome assessments were masked

106 a were age 1-4 years at the time of informed consent; fasting serum phosphorus concentration of less

107 We enrolled consenting FHS (Framingham Heart Study) participants in

108 izability, exclusion of patients too sick to consent, fluctuations in procedures in the standard arm

109 ), 371 completed the trial; parents withdrew consent for 1 child treated with hydrocortisone.

110 rocess, where patients or surrogates provide consent for all commonly performed procedures on a singl

111 confident that they obtained valid informed consent for critical care procedures with the use of bun

112 participant allocated chemotherapy withdrew consent for data use after randomisation and was exclude

113 Methods: All patients gave written informed consent for further utility of the biologic material.

114 ysis that excluded the patients who withdrew consent for participation in the trial or who were lost

115 r an Affirm test were enrolled with informed consent for the collection of additional specimens.

116 Consent for the extended follow-up was provided by 607 p

117 diac or intracranial procedure, inability to consent for themselves, or emergency surgery.

118 Subjects who had consented for genetic testing and who were of European a

119 Women were approached individually, they consented for study inclusion, and they were asked to gi

120 711 patients consented for targeted screening between April 1, 2015,

121 s, 46% (138) male, who gave written informed consent, for 4-year periods following randomisation.

122 tion and a suggestion for an updated patient consent form are presented.

123 p searches of records, reimbursed for signed consent forms, and supported by a dedicated clinician.

124 and June 19, 2014, we recruited and obtained consent from 4096 patients from 97 UK centres, of whom 1

125 d 407 patients, approached 185, and obtained consent from 51 (27.6%) patients.

126 ffairs (VA), aims to collect biosamples with consent from at least one million veterans.

127 racted from medical records, after obtaining consent from the patient's family.

128 72 hours after intubation following informed consent from their next of kin.

129 rived from a diploid assembly for the openly-consented Genome in a Bottle sample HG002.

130 ticipation, including inconsistent or absent consent guidance, guidelines that fail to account for th

131 rviews and specimens were collected from 565 consenting HCWs.

132 30 GMP-grade EBV-CTL lines from specifically consented healthy HCT donors.

133 Women were excluded after consenting if they lived too far from the centre of the

134 what constitutes best practice for informed consent in critical care.

135 ical template for obtaining patient informed consent in the future.

136 ysicians experienced with the use of bundled consent in the ICU held variable perceptions of its valu

137 of preference but the default is to presume consent; in both cases, the decision could be based on t

138 hs) were prospectively identified, and after consent, included in the study.

139 Among consenting individuals, the primary outcome was testing

140 ndomized trial was conducted in nonpregnant, consenting inpatient adults with rapid diagnostic test e

141 because of loss to follow-up, withdrawal of consent, investigator decision, and an unrelated death f

142 The authors also propose that patient consent is not required before the data are used for sec

143 d for secondary purposes when obtaining such consent is prohibitively costly or burdensome, as long a

144 ng explanations for the effect-a belief that consent is required to impose a policy on half of a popu

145 ibal services eligibility, 4) broad informed consent language, and 5) vague definitions of data acces

146 These new genomes have broad, open consent, making this a 'first of its kind' resource that

147 taff safety, infection control, the informed consent model, protocol complexity, data collection, and

148 uses of deidentified health information and consent models for oncology learning health care systems

149 Consent must be obtained from patients for return of res

150 xicity (n = 5), as a result of withdrawal of consent (n = 9), or at the treating physician's discreti

151 ective study was carried out on consecutive, consenting, newly-diagnosed patients with cirrhosis, in

152 t the effect on families and the validity of consent obtained with this strategy.

153 be screened with the PHQ-9 (40 women did not consent), of whom 333 (5.2%) screened positive for depre

154 ears or older, and provided written informed consent on behalf of themselves and their neonate.

155 included women and their newborn babies who consented on admission to hospital.

156 exclusion of 31 patients because of missing consent or mistaken or duplicate randomisation, 2196 alt

157 ld interventions are being conducted without consent or notice to the public they affect.

158 ten the only source of information regarding consent or refusal.

159 on group and 14 from the APBI group withdrew consent or were lost to follow-up at this stage, so 2039

160 informed about their bodies and the right to consent (or not) to sex.

161 ession, unacceptable toxicity, withdrawal of consent, or death.

162 ession, unacceptable toxicity, withdrawal of consent, or discontinuation by the investigator.

163 ession, unacceptable toxicity, withdrawal of consent, or physician decision.

164 require further ethical oversight, informed consent, or protections for vulnerable persons or commun

165 tment discontinuation, patient withdrawal of consent, or study end.

166 related to surgical care, including informed consent, pain management, difficult diagnoses and refusa

167 Consented participants selected their preferred IOL, whi

168 ed before 5 years of double-blind treatment, consenting participants could enrol in a double-blind ex

169 For this analysis, we included all consenting participants who were followed up with comple

170 multidrug regimens was feasible, with 49% of consented patients receiving personalized treatment.

171 A total of 1,854 consenting patients (50 Gy, n = 937; 40 Gy, n = 917) wer

172 iopsies were collected from the same area of consenting patients and assessed at baseline and on Day

173 spective, monocentric study of 24 eyes of 12 consenting patients diagnosed with SC, who underwent OCT

174 BEST PRACTICE ADVICE 12: When consenting patients for BET, the most common complicatio

175 of the respondents have duties that involve consenting patients for ophthalmic surgery and procedure

176 Atrial cells were obtained from consenting patients undergoing heart surgery, as well as

177 Paraffin-embedded tissues of 423 consenting patients were collected.

178 Consenting patients were prospectively followed for <=2

179 All consenting patients with atraumatic exudative ulcers of

180 hic and clinical data were collected for all consenting patients.

181 inician interviews, data are reported for 67 consenting patients.

182 ained to recruit, following informed written consent, patients diagnosed with HCC at oncology units a

183 framework included optimal pretest informed consent, post-test discussion, cascade testing, and tech

184 ial implications for LKD education, surgical consent, postdonation care, and outcome measurements.

185 Consenting pregnant women, aged 12-49 years, were recrui

186 demic medical center with a required bundled consent process actually obtain consent and how they per

187 ensure that surgical decision-making and the consent process for this procedure consider these long-t

188 dence-based practices and a careful informed consent process when choosing intravitreal antibiotics f

189 A bundled consent process, where patients or surrogates provide co

190 genetic information; and a detailed informed consent process.

191 , but current laws offer more disclosure and consent protections for research participants than for p

192 Similar recruitment and consent rates, few adverse events, and comparable outcom

193 ecruitment (aim: 1-2 patients/month/ICU) and consent rates, reasons for trial exclusion, protocol adh

194 Consent registrations are honored by the next-of-kin in

195 in a 1:1 fashion under exception to informed consent regulations to early coronary angiography versus

196 Our scoping review identified three consent-related strategies to expand adolescent inclusio

197 retrospective study, and waived the informed consent requirement.

198 xpand adolescent inclusion: waiving parental consent requirements, allowing adolescents to independen

199 arched for instances of UPD across 4,400,363 consented research participants from the personal geneti

200 ed 18-60 years who provided written informed consent, resided in the participating cluster catchment

201 Consenting respondents completed a two-part survey compo

202 mportant implications for patients' informed consent rights, clinicians' employment rights, and medic

203 Raising the legal age of sexual consent risks restricting adolescents from accessing the

204 To create this benchmark for a broadly consented son in a Personal Genome Project trio with bro

205 D-OCTs with device-designated operators from consented subjects.

206 de a more comprehensive understanding of the consent system for organ donation and some important nua

207 t process across different jurisdictions and consent systems.

208 s to account for the majority of the world's consent systems.

209 After excluding 19 participants who withdrew consent, there were 384 patients (mean age, 60 years; 29

210 If parents consented, there was an additional randomisation (1:1) o

211 Given appropriate consent, this could help identify people who are failing

212 Findings showed that the approach to gain consent to conduct the MITS procedure involves religious

213 ents reported feeling adequately informed to consent to diagnostic genomic sequencing.

214 oman in the concealed testing group withdrew consent to follow-up data collection, so 446 (>99%) wome

215 ares data from samples with a similarly open consent to increase the number of samples and population

216 that affirm 18 years as the minimum age for consent to marriage, international human-rights standard

217 ves) used a smartphone (Apple iPhone) app to consent to monitoring.

218 s (age range, 52-65 years) provided informed consent to participate in this cross-sectional study.

219 , and 30 (1%) children whose mothers did not consent to participate.

220 negative on the PHQ-9, and one woman did not consent to participate.

221 The partners of these women also had to consent to participate.

222 negative on the PHQ-9, and one woman did not consent to participate.

223 hical and practical challenges of adolescent consent to research participation in these countries.

224 eem to be a good potential mode of obtaining consent to supplement the harvesting of adequate tissues

225 women and 318 infants in the placebo group (consent to use data was withdrawn for 1 woman and 2 infa

226 microarray finding, 51 (10%) couples did not consent to WES or withdrew consent, and five (1%) sample

227 ed paraffin-embedded (FFPE) tumour biopsy or consented to a new biopsy at screening for the analysis

228 or screening and 6369 (99.4%) of these women consented to be screened with the PHQ-9 (40 women did no

229 and had a known BRAF(V600) mutant status or consented to BRAF(V600) mutation testing during screenin

230 aluation of dietary intake where 522 parents consented to completing >=1 component of data collection

231 Twenty-seven families consented to donation and 20 successful organ donations

232 atients were assessed for eligibility and 52 consented to enrolment.

233 urviving patients who were English speaking, consented to follow-up, and were randomized between Dece

234 mbers of the FHS Omni cohort (n=160) who had consented to genomic studies.

235 egravir arm and 168 in the efavirenz arm who consented to genotyping.

236 with normal allograft function (n = 70) who consented to have serum samples collected for research p

237 The majority of families (95%) consented to ICOD.

238 fetal heart sound at time of admission, and consented to inclusion.

239 e, 1819 households (one adult per household) consented to initial contact by the study team.

240 More people who have personally consented to organ donation via first person authorizati

241 identified, 1003 were eligible, of whom 625 consented to participate (n=335 exercise plus education

242 ves of patients with pulmonary fibrosis (PF) consented to participate in a screening study that inclu

243 Of the 1473 eligible residents, 953 consented to participate in the study (mean age, 86 year

244 Thirty-six of 50 sites (72%) consented to participate in the study, and 18 (50%) repo

245 Of 1132 women seeking abortion who consented to participate, 874 were included in this anal

246 ient departments/ICU/operation room; and (3) consented to participate.

247 dependent, and able to communicate, 83 (47%) consented to participate.

248 ildren in the corresponding weight bands who consented to pharmacokinetic studies and received the st

249 ng by center RESULTS:: A total of 1163 women consented to receive 18-month questionnaires of whom 730

250 current trial, consecutive patients with MDD consented to receive MST applied over the prefrontal cor

251 e risk in 3/85 (3.5%) newborns whose parents consented to receive this information.

252 mplication data were collected, and patients consented to receive validated PRO questionnaires at 18-

253 47% of screened patients consented to recruitment.

254 s in phase 3 licensure trials, virtually all consented to registry-based long-term follow-up.

255 g a large urban academic hospital system who consented to share access to their history of Facebook s

256 Participants consented to study procedures and provided usable activi

257 major depressive disorder were eligible and consented to take part.

258 A total of 288 patients (> 96%) consented to the QoL substudy.

259 neae are prelevated from body donors who had consented to the removal of tissues for transplantation

260 eb 11, 2015, and March 2, 2017, 310 patients consented to the study at 22 sites.

261 n both groups, all eligible participants who consented to the treatment and were at least 90 cm in he

262 fewer than one third of eligible individuals consented to vaccination.

263 indings (Glasgow Coma Scale score 13-15) who consented to venepuncture within 24 h post injury and wh

264 Patients remaining alive and consenting to participate had a follow-up visit during 2

265 1,641 year-one children with parent/guardian consent took part in baseline assessments prior to strat

266 uring, sharing of patient materials, patient consent, training, and communication with the public.

267 ients once every 3 weeks until withdrawal of consent, unacceptable toxicity, or progressive disease.

268 study perceived being adequately informed to consent, understood their child's results, and denied re

269 administered an online survey about bundled consent use to all residents.

270 Consent via driving license would seem to be a good pote

271 Consent was obtained from 40 patients (mean age, 58 yr [

272 local ethics committee and written informed consent was obtained from all participants.

273 the local ethics board and written informed consent was obtained from all participants.

274 Informed consent was obtained from potential enrollees.

275 Informed consent was obtained from the patient or next-of-kin.

276 Institutional-level consent was obtained, and all women presenting for mater

277 ts photographed abnormalities after maternal consent was obtained.

278 cted from contemporaneous notes, and patient consent was obtained.

279 Written informed consent was provided by all women who entered the trial.

280 h 1295 families were approached for consent; consent was provided for MITS by 963 (74%) of 1295 eligi

281 etrospective study, and a waiver of informed consent was received.

282 For neonates who died of those enrolled, consent was requested from parents for post-mortem exami

283 l ethics committee, and the need for patient consent was waived.

284 n study, four patients entered, one withdrew consent (week 24), three completed >=84 wk of treatment.

285 All patients who provided informed consent were included in the safety analysis.

286 l review board approval and informed patient consent were obtained.

287 ations influencing the preoperative informed consent were: smoking, operative technique, resection we

288 mary health-care centres, whose mothers gave consent, were tested by the HemoTypeSC point-of-care tes

289 , but may not require patient-level informed consent when the interventions being tested can be consi

290 Thus, only 3 of the 17 patients who consented while awaiting liver transplantation were dose

291 , arguments to align the legal age of sexual consent with that of marriage would restrict the ability

292 n = 4), completion of 10 cycles (n = 3), and consent withdrawal (n = 1).

293 reast cancer, intolerable adverse events, or consent withdrawal occurred.

294 sease progression, unacceptable toxicity, or consent withdrawal.

295 e participants in the placebo group withdrew consent without contributing a post-randomisation BCVA m

296 on-to-treat basis (participants who withdrew consent without contributing a post-randomisation BCVA m

297 tober 2013, and December 2016, we randomized consenting women within ART groups, using 1:1 permuted b

298 Of these consenting women, 46 were excluded (n=37 exercise plus e

299 Eligible consenting women, delivering within 42-60 days of enroll

300 Forty-two consented young adults, blinded to tooth surface allocat